Estrogen Receptor Negative: Clinical Trials

3 trials for Estrogen Receptor Negative, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Active not recruiting 2, Completed 1

Follow Estrogen Receptor Negative: new trials by email Literature Review of Estrogen Receptor Negative trials Research Report on Estrogen Receptor Negative

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Capecitabine, Carboplatin, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative
Phase 3Active not recruitingECOG-ACRIN Cancer Research Group4152015-10-202026-11-02
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride - Breast Adenocarcinoma, Estrogen Receptor Negative
Phase 3Active not recruitingNRG Oncology7822015-07-262026-05-06
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive
Phase 3CompletedNational Cancer Institute (NCI)7992008-10-132026-06-23

Narrower conditions

Breast Neoplasms (3)  ·  Triple Negative Breast Neoplasms (2)

Broader conditions

Breast Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Skin Diseases (3)  ·  Skin and Connective Tissue Diseases (3)

Interventions

Carboplatin (2)  ·  Paclitaxel (2)  ·  Taxes (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Bevacizumab (1)  ·  Capecitabine (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Disulfides (1)  ·  Doxorubicin (1)  ·  Epothilones (1)  ·  Immunoglobulin G (1)  ·  ixabepilone (1)

Sponsors

ECOG-ACRIN Cancer Research Group (1)  ·  NRG Oncology (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (3)  ·  Canada (1)  ·  Puerto Rico (1)  ·  South Africa (1)

Top investigators

Hope S Rugo (1)  ·  Ingrid Mayer (1)  ·  Vicente Valero (1)

Results publications

PMID 26056183, PMID 28620884, PMID 34092112, PMID 34616010, PMID 38236702, PMID 39169033

NIH funding

U10CA031946 (1), U10CA180820 (1), U10CA180821 (1), U10CA180868 (1), U24CA196172 (1)